<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:regn="http://regeneron.com/20200706">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" /></head>
<!-- Field: Set; Name: xdx; ID: xdx_029_US%2DGAAP%2D2020 -->
<!-- Field: Set; Name: xdx; ID: xdx_03E_regn_regeneron.com_20200706 -->
<!-- Field: Set; Name: xdx; ID: xdx_044_20200706_20200706 -->
<!-- Field: Set; Name: xdx; ID: xdx_057_edei%2D%2DEntityCentralIndexKey_0000872589 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
  <ix:hidden>
    <ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:EntityCentralIndexKey">0000872589</ix:nonNumeric>
    <ix:nonNumeric contextRef="From2020-07-06to2020-07-06" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
    </ix:hidden>
  <ix:references>
    <link:schemaRef xlink:href="regn-20200706.xsd" xlink:type="simple" />
    </ix:references>
  <ix:resources>
    <xbrli:context id="From2020-07-06to2020-07-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000872589</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-06</xbrli:startDate>
        <xbrli:endDate>2020-07-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    </ix:resources>
  </ix:header>
</div>


<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0pt 0">&#160;</p>

<p style="margin: 0pt 0"></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90A_edei--DocumentType_c20200706__20200706_zWVVENqV9L53"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 13.5pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event
reported): July 7, 2020 (<span id="xdx_90E_edei--DocumentPeriodEndDate_c20200706__20200706_zmmfB1cZliXj"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July 6, 2020</ix:nonNumeric></span>)</b></p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 22pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90A_edei--EntityRegistrantName_c20200706__20200706_zJbsSxRJahyh"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:EntityRegistrantName">REGENERON PHARMACEUTICALS, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of registrant as specified
in its charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityIncorporationStateCountryCode_c20200706__20200706_zGXjwAxtwa11"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">New York</ix:nonNumeric></span></b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(State or other jurisdiction of incorporation)</b></p>

<p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 51%"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityFileNumber_c20200706__20200706_zAKp3xGVJKO5"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:EntityFileNumber">000-19034</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal; width: 48%"><span style="font-size: 10pt"><b><span id="xdx_90F_edei--EntityTaxIdentificationNumber_c20200706__20200706_zfAYLgWvHrJ4"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:EntityTaxIdentificationNumber">13-3444607</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>File Number)</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></p>
        <p style="font: 8pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p>
        <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></td></tr>
<tr>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_904_edei--EntityAddressAddressLine1_c20200706__20200706_zsgbPEbInSv3"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:EntityAddressAddressLine1">777 Old Saw Mill River Road</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressCityOrTown_c20200706__20200706_z8CKg12FeiGi"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:EntityAddressCityOrTown">Tarrytown</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20200706__20200706_zpMusLkvQuLf"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">New York</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: bottom; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><b><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20200706__20200706_zHkgfYLXD7Ac"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:EntityAddressPostalZipCode">10591-6707</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 8pt"><b>(Address of principal executive offices)</b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="font-size: 10pt; text-align: center; vertical-align: top; font-size-adjust: none; font-stretch: normal"><span style="font-size: 8pt"><b>(Zip Code)</b></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Registrant&#8217;s telephone number,
including area code: (<span id="xdx_90B_edei--CityAreaCode_c20200706__20200706_zO5NCpeYKG1e"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:CityAreaCode">914</ix:nonNumeric></span>) <span id="xdx_90E_edei--LocalPhoneNumber_c20200706__20200706_zeJgLWWWujM6"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:LocalPhoneNumber">847-7000</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_908_edei--WrittenCommunications_c20200706__20200706_zmbWyB5HBgP3"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span> Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_909_edei--SolicitingMaterial_c20200706__20200706_zkxB2D5pmI68"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20200706__20200706_zOMoW30hp3Lk"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90C_edei--PreCommencementIssuerTenderOffer_c20200706__20200706_z5qNfN9sBFtc"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border: black 1pt solid; font-size: 10pt; border-image: none; width: 42%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Title of each class</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; width: 20%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Trading Symbol(s)</span></td>
    <td style="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; width: 38%; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt">Name of each exchange on which registered</span></td></tr>
<tr style="vertical-align: top">
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_904_edei--Security12bTitle_c20200706__20200706_zJJyheLcxza8"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:Security12bTitle">Common Stock &#8211; par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_902_edei--TradingSymbol_c20200706__20200706_z66X84fiaux1"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" name="dei:TradingSymbol">REGN</ix:nonNumeric></span></span></td>
    <td style="border-right: black 1pt solid; border-bottom: black 1pt solid; font-size: 10pt; text-align: center; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; font-size-adjust: none; font-stretch: normal"><span style="font-size: 10pt"><span id="xdx_901_edei--SecurityExchangeName_c20200706__20200706_zxtIziazeuNl"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq Global Select Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167; 240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Wingdings"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20200706__20200706_zhkwDFqet6V"><ix:nonNumeric contextRef="From2020-07-06to2020-07-06" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01.&#160; Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On July 6, 2020, Regeneron Pharmaceuticals,
Inc. (&#8220;<span style="text-decoration: underline">Regeneron</span>&#8221; or the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) entered into a Base Agreement (the &#8220;<span style="text-decoration: underline">Base Agreement</span>&#8221;)
and associated Project Agreement (the &#8220;<span style="text-decoration: underline">Project Agreement</span>&#8221;) with Advanced Technology International, Inc. (&#8220;<span style="text-decoration: underline">ATI</span>&#8221;),
an entity acting on behalf of the Medical CBRN Defense Consortium (&#8220;<span style="text-decoration: underline">MCDC</span>&#8221;), under the authority of the Other
Transaction Agreement No. W15QKN-16-9-1002 between ATI, on behalf of MCDC, and the U.S. Department of Defense (the Base Agreement,
together with the Project Agreement, the &#8220;<span style="text-decoration: underline">MCDC Agreement</span>&#8221;), to manufacture and deliver to the U.S. Government
the Company&#8217;s novel investigational dual antibody &#8220;cocktail&#8221; treatment, consisting of the two antibodies REGN10987
and REGN10933 (also known as REGN-COV2), or other fully human monoclonal antibodies (as monotherapies or a cocktail) as agreed
to in writing between Regeneron and the U.S. Government, designed to prevent or treat COVID-19. The MCDC Agreement could result
in payments to Regeneron of up to $450.2 million in the aggregate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
MCDC Agreement requires Regeneron to produce and deliver to the U.S. Government drug product, with a specified minimum and maximum
commitment for the total amount of filled and finished drug product delivered. Of the aggregate $450.2 million maximum amount payable
to Regeneron under the MCDC Agreement, $445.0 million is payable for achievement of quarterly drug product manufacturing milestones
and $5.2 million is payable for drug product storage. The MCDC Agreement provides for bulk manufacturing of the drug substance
beginning in the summer of 2020 through the fall of 2020 and also provides for fill/finish and storage activities by Regeneron</span>
starting in the third quarter of 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The MCDC Agreement contains terms and conditions
that are customary for U.S. Government agreements of this nature, including provisions giving the U.S. Government the right to
terminate the Base Agreement and/or the Project Agreement based on a reasonable determination that the project funded under the
MCDC Agreement will not produce beneficial results commensurate with the expenditure of resources and that termination would be
in the U.S. Government&#8217;s interest. If the Project Agreement is terminated prior to completion, Regeneron is entitled to be
paid certain termination costs, including the price of any drug product manufactured under the MCDC Agreement and not yet paid,
a prorated portion of the price for drug substance or drug product that is in-process (based on the stage of production), certain
third-party reservation and cancellation fees, and certain raw material costs incurred by Regeneron. The performance period under
the Project Agreement extends from June 30, 2020 through June 30, 2021.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
foregoing description of the </span>MCDC Agreement is qualified in its entirety by reference to the full text of the MCDC Agreement.
A copy of each of the Base Agreement and the Project Agreement will be filed with the U.S. Securities and Exchange Commission as
an exhibit to the Company&#8217;s Quarterly Report on Form&#160;10-Q for the quarterly period ending September 30, 2020.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7.01.&#160; Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">There is no impact on Regeneron&#8217;s
results of operations for the second quarter of 2020 as a consequence of entering into the MCDC Agreement. Regeneron will provide
updated full year 2020 financial guidance, including the anticipated impact of the MCDC Agreement transaction on Regeneron&#8217;s
results of operations, as part of Regeneron&#8217;s second quarter 2020 earnings announcement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr>
<td style="vertical-align: top; width: 50%">&#160;</td>
<td style="width: 50%"><b>REGENERON PHARMACEUTICALS, INC.&#160; &#160;</b></td>
</tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td>&#160;</td></tr>
<tr>
<td style="vertical-align: top">&#160;</td>
<td>&#160;</td></tr>
<tr>
<td>&#160;</td>
<td style="border-bottom: black 1pt solid">/s/ Joseph J. LaRosa</td>
</tr>
<tr>
<td>&#160;</td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Joseph J. LaRosa</span></td>
</tr>
<tr>
<td>&#160;</td>
<td style="font-size: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Executive Vice President, General Counsel and Secretary</span></td>
</tr>
<tr>
<td colspan="2">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: July 7, 2020</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fk38Ae2bFhWxihQRX2O7SrDNlk38O5K3NLaIy8KyzHwzQnTEkhamRIbjLEthj1Vdao+Q4RkZbY7BkazWMYSb4cU4z9r65v2BCQUGAzPqylMehMZ6Nw6LGOS4J1VPTUAOYzWA6UZEXz0hezYFWm90CdoWsGOq2aDX/GoT9vpJlqpXU3VAdoZsDKorW/kNfan6sKW7fhBfHaRpIqJOM5FYMt3qb83NeapgXmIVulyL/jf6ADFtSWw= -->
